REFERENCES
1. Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta Biomembr 1976;455:152-62.
2. Davidson AL, Dassa E, Orelle C, Chen J. Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev 2008;72:317-64, table of contents.
4. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr 2001;33:453-8.
6. Thomas C, Aller SG, Beis K, et al. Structural and functional diversity calls for a new classification of ABC transporters. FEBS Lett 2020;594:3767-75.
7. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42:1007-17.
9. Lewinson O, Orelle C, Seeger MA. Structures of ABC transporters: handle with care. FEBS Lett 2020;594:3799-814.
10. Senior AE, al-Shawi MK, Urbatsch IL. The catalytic cycle of P-glycoprotein. FEBS Lett 1995;377:285-9.
11. Qu Q, Russell PL, Sharom FJ. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle. Biochemistry 2003;42:1170-7.
12. Sharom FJ. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 2006;84:979-92.
13. Bársony O, Szalóki G, Türk D, et al. A single active catalytic site is sufficient to promote transport in P-glycoprotein. Sci Rep 2016;6:24810.
14. Zwick M, Esposito C, Hellstern M, Seelig A. How phosphorylation and ATPase activity regulate anion flux though the cystic fibrosis transmembrane conductance regulator (CFTR). J Biol Chem 2016;291:14483-98.
15. Sauna ZE, Smith MM, Müller M, Kerr KM, Ambudkar SV. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001;33:481-91.
16. Rosenberg MF, Mao Q, Holzenburg A, Ford RC, Deeley RG, Cole SP. The structure of the multidrug resistance protein 1 (MRP1/ABCC1). crystallization and single-particle analysis. J Biol Chem 2001;276:16076-82.
17. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004;11:918-26.
18. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006;443:180-5.
19. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22.
20. Li J, Jaimes KF, Aller SG. Refined structures of mouse P-glycoprotein. Protein Sci 2014;23:34-46.
22. Thomas C, Tampé R. Structural and mechanistic principles of ABC transporters. Annu Rev Biochem 2020;89:605-36.
23. Lusvarghi SRRGM, Ambudkar SV. Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. F1000Res 2020;9:F1000 Faculty Rev-17.
24. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 1990;265:3975-80.
25. Bruggemann E, Currier S, Gottesman M, Pastan I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 1992;267:21020-6.
26. Homolya L, Holló Z, Germann U, Pastan I, Gottesman M, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993;268:21493-6.
27. Doige CA, Yu X, Sharom FJ. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim Biophys Acta Biomembr 1993;1146:65-72.
28. Beis I, Newsholme EA. The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. Biochem J 1975;152:23-32.
29. Ataullakhanov FI, Vitvitsky VM. What determines the intracellular ATP concentration. Biosci Rep 2002;22:501-11.
30. Yaginuma H, Kawai S, Tabata KV, et al. Diversity in ATP concentrations in a single bacterial cell population revealed by quantitative single-cell imaging. Sci Rep 2014;4:6522.
31. Sharom FJ, Liu R, Qu Q, Romsicki Y. Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol 2001;12:257-65.
32. Beck A, Aänismaa P, Li-Blatter X, Dawson R, Locher K, Seelig A. Sav1866 from Staphylococcus aureus and P-glycoprotein: similarities and differences in ATPase activity assessed with detergents as allocrites. Biochemistry 2013;52:3297-309.
33. Xu Y, Seelig A, Bernèche S. Unidirectional transport mechanism in an ATP dependent exporter. ACS Cent Sci 2017;3:250-8.
34. Velamakanni S, Yao Y, Gutmann DA, van Veen HW. Multidrug transport by the ABC transporter Sav1866 from Staphylococcus aureus. Biochemistry 2008;47:9300-8.
35. Seelig A. P-Glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers. Front Oncol 2020;10:576559.
37. Lorent JH, Levental KR, Ganesan L, et al. Plasma membranes are asymmetric in lipid unsaturation, packing and protein shape. Nat Chem Biol 2020;16:644-52.
38. Seelig J, Seelig A. Lipid conformation in model membranes and biological membranes. Q Rev Biophys 1980;13:19-61.
39. Seelig A, Seelig J. Membrane structure. In: Encyclopedia of physical science and technology. Academic Press; 2002. p. 355-67.
40. Gally HU, Seelig A, Seelig J. Cholesterol-induced rod-like motion of fatty acyl chains in lipid bilayers a deuterium magnetic resonance study. Hoppe Seylers Z Physiol Chem 1976;357:1447-50.
41. Ferreira TM, Coreta-Gomes F, Ollila OH, Moreno MJ, Vaz WL, Topgaard D. Cholesterol and POPC segmental order parameters in lipid membranes: solid state 1H-13C NMR and MD simulation studies. Phys Chem Chem Phys 2013;15:1976-89.
42. Jost PC, Griffith OH, Capaldi RA, Vanderkooi G. Evidence for boundary lipid in membranes. Proc Natl Acad Sci U S A 1973;70:480-4.
43. Oldfield E, Gilmore R, Glaser M, et al. Deuterium nuclear magnetic resonance investigation of the effects of proteins and polypeptides on hydrocarbon chain order in model membrane systems. Proc Natl Acad Sci USA 1978;75:4657-60.
44. Seelig A, Seelig J. Lipid-protein interaction in reconstituted cytochrome c oxidase/phospholipid membranes. Hoppe Seylers Z Physiol Chem 1978;359:1747-56.
45. Kang SY, Kinsey RA, Rajan S, Gutowsky HS, Gabridge MG, Oldfield E. Protein-lipid interactions in biological and model membrane systems. Deuterium NMR of Acholeplasma laidlawii B, Escherichia coli, and cytochrome oxidase systems containing specifically deuterated lipids. J Biol Chem 1981;256:1155-9.
46. Tamm LK, Seelig J. Lipid solvation of cytochrome c oxidase. Deuterium, nitrogen-14, and phosphorus-31 nuclear magnetic resonance studies on the phosphocholine head group and on cis-unsaturated fatty acyl chains. Biochemistry 1983;22:1474-83.
47. Seelig A, Seelig J. Phospholipid composition and organization of cytochrome c oxidase preparations as determined by 31P-nuclear magnetic resonance. Biochim Biophys Acta Biomembr 1985;815:153-8.
48. Schote U, Ganz P, Fahr A, Seelig J. Interactions of cyclosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry. J Pharm Sci 2002;91:856-67.
49. Nyholm TK, van Duyl B, Rijkers DT, Liskamp RM, Killian JA. Probing the lipid-protein interface using model transmembrane peptides with a covalently linked acyl chain. Biophys J 2011;101:1959-67.
50. Scherer PG, Seelig J. Structure and dynamics of the phosphatidylcholine and the phosphatidylethanolamine head group in L-M fibroblasts as studied by deuterium nuclear magnetic resonance. EMBO J 1987;6:2915-22.
51. Heerklotz H, Wieprecht T, Seelig J. Membrane perturbation by the lipopeptide surfactin and detergents as studied by deuterium NMR. J Phys Chem B 2004;108:4909-15.
52. Wenk M, Alt T, Seelig A, Seelig J. Octyl-beta-D-glucopyranoside partitioning into lipid bilayers: thermodynamics of binding and structural changes of the bilayer. Biophys J 1997;72:1719-31.
53. Meier M, Seelig J. Lipid and peptide dynamics in membranes upon insertion of n-alkyl-beta-D-glucopyranosides. Biophys J 2010;98:1529-38.
54. Veatch S, Polozov I, Gawrisch K, Keller S. Liquid Domains in Vesicles Investigated by NMR and Fluorescence Microscopy. Biophys J 2004;86:2910-22.
55. Eggeling C, Ringemann C, Medda R, et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 2009;457:1159-62.
56. Seelig A. The use of monolayers for simple and quantitative analysis of lipid-drug interactions exemplified with dibucaine and substance P. Cell Biol Int Rep 1990;14:369-80.
57. Taschner N. Partitioning of local anesthetic into membranes composed of POPC/cholesterol [Diploma Thesis]. Basel: University of Basel; 1992.
58. Seelig A. The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J Mol Neurosci 2007;33:32-41.
59. Gatlik-Landwojtowicz E, Aänismaa P, Seelig A. Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 2006;45:3020-32.
60. Huang W, Levitt D. Theoretical calculation of the dielectric constant of a bilayer membrane. Biophys J 1977;17:111-28.
61. Kimura Y, Ikegami A. Local dielectric properties around polar region of lipid bilayer membranes. J Membr Biol 1985;85:225-31.
62. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
63. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci 1992;17:18-21.
64. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998;251:252-61.
65. Seelig A. How does P-glycoprotein recognize its substrates? Int J Clin Pharmacol Ther 1998;36:50.
66. Egido E, Müller R, Li-Blatter X, Merino G, Seelig A. Predicting activators and inhibitors of the breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) based on mechanistic considerations. Mol Pharm 2015;12:4026-37.
67. Xu Y, Egido E, Li-Blatter X, et al. Allocrite sensing and binding by the breast cancer resistance protein (ABCG2) and P-Glycoprotein (ABCB1). Biochemistry 2015;54:6195-206.
68. Nabekura T, Kawasaki T, Kato Y, et al. Citrus auraptene induces drug efflux transporter P-glycoprotein expression in human intestinal cells. Food Funct 2020;11:5017-23.
69. Nervi P, Li-Blatter X, Aänismaa P, Seelig A. P-glycoprotein substrate transport assessed by comparing cellular and vesicular ATPase activity. Biochim Biophys Acta 2010;1798:515-25.
70. Srinivasan V, Pierik AJ, Lill R. Crystal structures of nucleotide-free and glutathione-bound mitochondrial ABC transporter Atm1. Science 2014;343:1137-40.
71. Nosol K, Romane K, Irobalieva RN, et al. Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1. Proc Natl Acad Sci USA 2020;117:26245-53.
72. Alam A, Kowal J, Broude E, Roninson I, Locher KP. Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science 2019;363:753-6.
73. Urgaonkar S, Nosol K, Said AM, et al. Discovery and characterization of potent dual P-Glycoprotein and CYP3A4 inhibitors: design, synthesis, Cryo-EM analysis, and biological evaluations. J Med Chem 2022;65:191-216.
74. Dawson RJ, Locher KP. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett 2007;581:935-8.
75. Ward A, Reyes CL, Yu J, Roth CB, Chang G. Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc Natl Acad Sci USA 2007;104:19005-10.
76. Litman T, Nielsen D, Skovsgaard T, Zeuthen T, Stein WD. ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines. Biochim Biophys Acta Mol Basis Dis 1997;1361:147-58.
77. Al-Shawi MK, Polar MK, Omote H, Figler RA. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem 2003;278:52629-40.
78. Aänismaa P, Seelig A. P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells. Biochemistry 2007;46:3394-404.
79. Li-Blatter X, Beck A, Seelig A. P-glycoprotein-ATPase modulation: the molecular mechanisms. Biophys J 2012;102:1383-93.
80. Seelig J, Ganz P. Nonclassical hydrophobic effect in membrane binding equilibria. Biochemistry 1991;30:9354-9.
81. Li-Blatter X, Seelig A. Exploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers. Biophys J 2010;99:3589-98.
82. Li-Blatter X, Nervi P, Seelig A. Detergents as intrinsic P-glycoprotein substrates and inhibitors. Biochim Biophys Acta 2009;1788:2335-44.
83. Romsicki Y, Sharom FJ. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 1999;38:6887-96.
84. Clay AT, Sharom FJ. Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. Biochemistry 2013;52:343-54.
85. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-8.
86. Broxterman HJ, Pinedo HM, Kuiper CM, Kaptein LC, Schuurhuis GJ, Lankelma J. Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J 1988;2:2278-82.
87. Sarkadi B, Price E, Boucher R, Germann U, Scarborough G. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992;267:4854-8.
88. Sarkadi B, Müller M, Homolya L, et al. Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J 1994;8:766-70.
89. Doige CA, Yu X, Sharom FJ. ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta Biomembr 1992;1109:149-60.
90. Al-Shawi MK, Senior AE. Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein. J Biol Chem 1993;268:4197-206.
91. Callaghan R, Berridge G, Ferry DR, Higgins CF. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. Biochim Biophys Acta Biomembr 1997;1328:109-24.
92. Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995;228:1020-9.
93. Meier M, Blatter XL, Seelig A, Seelig J. Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity. Biophys J 2006;91:2943-55.
94. Aanismaa P, Gatlik-Landwojtowicz E, Seelig A. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle. Biochemistry 2008;47:10197-207.
95. Kabanov A. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic® block copolymers. J Control Release 2003;91:75-83.
96. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta Mol Basis Dis 1997;1361:159-68.
97. Moncelli M, Becucci L, Guidelli R. The intrinsic pKa values for phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine in monolayers deposited on mercury electrodes. Biophys J 1994;66:1969-80.
98. Kornberg RD, McConnell HM. Inside-outside transitions of phospholipids in vesicle membranes. Biochemistry 1971;10:1111-20.
99. Romsicki Y, Sharom FJ. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 2001;40:6937-47.
100. Chufan EE, Kapoor K, Ambudkar SV. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein. Biochem Pharmacol 2016;101:40-53.
101. Sasitharan K, Iqbal HA, Bifsa F, Olszewska A, Linton KJ. ABCB1 does not require the side-chain hydrogen-bond donors Gln347, Gln725, Gln990 to confer cellular resistance to the anticancer drug taxol. Int J Mol Sci 2021;22:8561.
102. Tombline G, Donnelly DJ, Holt JJ, et al. Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the “R” site to the ATP hydrolysis transition state. Biochemistry 2006;45:8034-47.
104. Ben-tal N, Sitkoff D, Topol IA, Yang A, Burt SK, Honig B. Free energy of amide hydrogen bond formation in vacuum, in water, and in liquid alkane solution. J Phys Chem B 1997;101:450-7.
105. Arbely E, Arkin IT. Experimental measurement of the strength of a Cα-H···O bond in a lipid bilayer. J Am Chem Soc 2004;126:5362-3.
106. Joh NH, Min A, Faham S, et al. Modest stabilization by most hydrogen-bonded side-chain interactions in membrane proteins. Nature 2008;453:1266-70.
107. Perez C, Mehdipour AR, Hummer G, Locher KP. Structure of outward-facing PglK and molecular dynamics of lipid-linked oligosaccharide recognition and translocation. Structure 2019;27:669-678.e5.
108. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 1992;89:8472-6.
109. Urbatsch IL, al-Shawi MK, Senior AE. Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 1994;33:7069-76.
110. Rothnie A, Theron D, Soceneantu L, et al. The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence. Eur Biophys J 2001;30:430-42.
111. Clouser AF, Alam YH, Atkins WM. Cholesterol asymmetrically modulates the conformational ensemble of the nucleotide-binding domains of P-glycoprotein in lipid nanodiscs. Biochemistry 2021;60:85-94.
112. Shukla S, Abel B, Chufan EE, Ambudkar SV. Effects of a detergent micelle environment on P-glycoprotein (ABCB1)-ligand interactions. J Biol Chem 2017;292:7066-76.
113. Kimura Y, Kioka N, Kato H, Matsuo M, Ueda K. Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J 2007;401:597-605.
114. Eckford PD, Sharom FJ. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 2008;47:13686-98.
115. Gayet L, Dayan G, Barakat S, et al. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemistry 2005;44:4499-509.
116. Stein WD. Kinetics of the P-glycoprotein, the multidrug transporter. Exp Physiol 1998;83:221-32.
117. McConnell HM, Owicki JC, Parce JW, et al. The cytosensor microphysiometer: biological applications of silicon technology. Science 1992;257:1906-12.
118. Owicki JC, Parce JW, Kercso KM, et al. Continuous monitoring of receptor-mediated changes in the metabolic rates of living cells. Proc Natl Acad Sci USA 1990;87:4007-11.
119. Lin SJ, Kaeberlein M, Andalis AA, et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature 2002;418:344-8.
120. Landwojtowicz E, Nervi P, Seelig A. Real-time monitoring of P-glycoprotein activation in living cells. Biochemistry 2002;41:8050-7.
121. Mandel LJ, Balaban RS. Stoichiometry and coupling of active transport to oxidative metabolism in epithelial tissues. Am J Physiol 1981;240:F357-71.
122. Omote H, Al-Shawi MK. A novel electron paramagnetic resonance approach to determine the mechanism of drug transport by P-glycoprotein. J Biol Chem 2002;277:45688-94.
123. Eytan GD, Regev R, Assaraf YG. Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. J Biol Chem 1996;271:3172-8.
124. Ambudkar SV, Cardarelli CO, Pashinsky I, Stein WD. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J Biol Chem 1997;272:21160-6.
125. Wenk MR, Fahr A, Reszka R, Seelig J. Paclitaxel partitioning into lipid bilayers. J Pharm Sci 1996;85:228-31.
126. Shapiro AB, Ling V. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. Eur J Biochem 1998;254:189-93.
127. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta Mol Basis Dis 1997;1361:169-76.
128. Marzolini C, Mueller R, Li-Blatter X, Battegay M, Seelig A. The brain entry of HIV-1 protease inhibitors is facilitated when used in combination. Mol Pharm 2013;10:2340-9.
129. Seelig A, Alt T, Lotz S, Hölzemann G. Binding of substance P agonists to lipid membranes and to the neurokinin-1 receptor. Biochemistry 1996;35:4365-74.
130. Huang SC, Korlipara VL. Neurokinin-1 receptor antagonists: a comprehensive patent survey. Expert Opin Ther Pat 2010;20:1019-45.
131. Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009;26:1816-31.
132. Gerebtzoff G, Seelig A. In silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J Chem Inf Model 2006;46:2638-50.
133. Spletstoser JT, Turunen BJ, Desino K, et al. Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells. Bioorg Med Chem Lett 2006;16:495-8.
134. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18:452-64.
135. Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011;50:209-32.
136. Omote H, Al-Shawi MK. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J 2006;90:4046-59.
